NOV 17, 202655 MINS READ
Creatine phosphate (N-phosphorylcreatine, phosphocreatine) is characterized by the molecular formula C₄H₁₀N₃O₅P with a phosphate group esterified to the guanidino nitrogen of creatine 3. The compound exists predominantly as disodium or dipotassium salts in pharmaceutical preparations to enhance aqueous solubility and stability 2,5. The structural formula features a phosphoramidate bond linking the phosphate moiety to the N-methyl guanidine backbone, which is critical for its role as a high-energy phosphagen 3,8.
Key structural variants include:
The chemical structure directly influences specifications such as hygroscopicity (tetrahydrate forms absorb 4 moles of water per mole of salt), pH stability profiles, and susceptibility to hydrolytic degradation to creatine and inorganic phosphate 2,14.
Pharmaceutical-grade creatine phosphate specifications mandate purity levels ≥99.0% as determined by high-performance liquid chromatography (HPLC) with evaporative light scattering detection (ELSD) 2. Critical impurity profiles include:
A validated HPLC method employs reverse-phase chromatography with ELSD, achieving sensitivity sufficient to detect impurities at 0.01% levels 2. The method utilizes a mobile phase gradient optimized for separation of creatine phosphate from structurally related substances, with retention times typically in the range of 8-12 minutes under standard conditions 2. Alternative detection methods include UV spectrophotometry at 210-220 nm, though ELSD provides superior sensitivity for non-chromophoric impurities 2.
For research applications, additional specifications include:
Creatine phosphate disodium salt exhibits high aqueous solubility, typically >250 mg/mL at room temperature (22°C), facilitating formulation of concentrated injectable solutions 6. Solubility is pH-dependent, with maximum stability and solubility observed in the pH range 6.5-8.0 4,6. At pH values below 5.0, the phosphoramidate bond becomes increasingly susceptible to acid-catalyzed hydrolysis, while alkaline conditions (pH >9.0) promote base-catalyzed degradation and epimerization 6,14.
Stability studies of creatinol O-phosphate aqueous solutions (250 mg/mL) demonstrate remarkable resistance to degradation across pH ranges 3.0-7.0 when stored at temperatures from 4°C to 40°C for up to 60 days, with creatinine formation remaining below detection limits (<0.01 mg/mL) 6. This contrasts with standard creatine monohydrate, which undergoes significant cyclization to creatinine under similar conditions 6.
Thermal analysis reveals that crystalline creatine phosphate disodium tetrahydrate undergoes dehydration in multiple stages:
The anhydrous form exhibits a melting point with decomposition at 243-244°C for creatinol O-phosphate 18. For pharmaceutical storage, specifications typically require:
Accelerated stability studies (40°C/75% RH) demonstrate that properly formulated creatine phosphate disodium maintains >98% purity for 6 months, with degradation products (primarily inorganic phosphate and creatine) increasing linearly at approximately 0.1-0.2% per month 2,6.
The tetrahydrate form exhibits moderate hygroscopicity, absorbing additional moisture above 70% relative humidity, which can lead to deliquescence and accelerated degradation 4. Specifications for water content by Karl Fischer titration typically range from 20.0-22.0% for the tetrahydrate (theoretical: 22.0%), with tighter control (±0.5%) required for pharmaceutical batches 2,4. Anhydrous forms, while more stable to hydrolysis, are more hygroscopic and require stringent moisture control during manufacturing and storage 5.
The classical enzymatic route employs creatine kinase-catalyzed phosphorylation of creatine using 3-phosphoglyceric acid as the phosphate donor in the presence of catalytic ATP 14. Key process parameters include:
Post-reaction processing involves:
This method yields 300-350 g creatine phosphate disodium hexahydrate per 100 L batch (yield 50-60% based on creatine input) with purity >99.0% after recrystallization 14.
Modern continuous-flow synthesis employs phosphoryl chloride (POCl₃) as the phosphorylating agent, offering advantages in scalability and cost-efficiency 19. The process comprises:
Step 1: Creatinine phosphorylation
Step 2: Hydrolysis and neutralization
Step 3: Purification
This continuous-flow method reduces POCl₃ usage by 30-40% compared to batch processes, minimizes phosphate impurities to <0.3%, and achieves overall yields of 65-75% with purity >99.5% 19. Critical process specifications include:
Creatinol O-phosphate synthesis employs creatinol sulfate as starting material, reacted with concentrated sulfuric acid to form a protected intermediate, followed by phosphorylation with POCl₃, ClPO₃H₂, or P₂O₅ 13,18. Key advantages include:
Process specifications:
Creatine phosphate sodium for injection is formulated as sterile, pyrogen-free solutions or lyophilized powders for reconstitution 4. Typical specifications include:
Stability specifications for injectable solutions require:
Oral creatine phosphate sodium formulations address the challenge of gastrointestinal instability through enteric coating and absorption enhancers 4. Specifications include:
Core tablet composition:
Enteric coating system:
Stability testing demonstrates that enteric-coated tablets maintain >95% potency for
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| XENOPORT INC. | Treatment of ischemia, heart failure, and neurodegenerative disorders requiring enhanced cellular energy homeostasis and ATP regeneration. | Creatine Phosphate Prodrug Formulations | Membrane permeable prodrugs achieve enhanced bioavailability and cellular uptake through improved membrane permeability, enabling effective treatment of energy metabolism disorders. |
| SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD. | Quality control and intermediate inspection during creatine phosphate disodium salt synthesis for pharmaceutical manufacturing and injectable formulations. | Creatine Phosphate Disodium Salt Quality Control System | High-performance liquid chromatography with evaporative light scattering detection achieves high sensitivity and reliable determination of impurities including inorganic phosphate below 0.5%, ensuring pharmaceutical-grade purity >99.0%. |
| HARBIN BOLAI PHARMACEUTICAL CO. LTD. | Oral administration for cardiac and skeletal muscle protection in patients requiring myocardial ischemia treatment and energy metabolism support. | Creatine Phosphate Sodium Oral Solid Preparations | Enteric-coated formulations with L-glutamine and sodium lactate achieve good stability, reduced loss rate during preparation, and protection against gastrointestinal degradation, enabling oral delivery of creatine phosphate. |
| CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD. | Large-scale pharmaceutical manufacturing of creatine phosphate sodium with enhanced safety, reduced toxic byproducts, and improved production efficiency. | Continuous Flow Synthesis System for Creatine Phosphate Sodium | Micro-channel reactor technology reduces phosphorus oxychloride usage by 30-40%, minimizes phosphate impurities to <0.3%, and achieves yields of 65-75% with purity >99.5% through optimized continuous-flow processing. |
| TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD. | Pharmaceutical production of creatinol O-phosphate analog with improved safety and reduced environmental impact for cardioprotective and neuroprotective applications. | Creatinol O-Phosphate Synthesis Process | Novel synthesis route using creatinol sulfate eliminates toxic S-ethyl isothiourea hydrobromide, achieves 60-85% yield with 99.05% purity after recrystallization, and reduces sulfur-containing byproducts for enhanced safety profile. |